While Japan has now granted its first emergency approval to Shionogi’s COVID-19 pill Xocova (ensitrelvir), the drug failed to win a unanimous vote by advisory panels, with skepticism lingering over its actual efficacy. To prep for the next emergency, which…
HOME > COLUMN
COLUMN
- The Power in Teaching Your Team “How to Speak”
May 28, 2019
- Unlock Hidden Talent by Hiring for These Four Traits
May 10, 2019
- No Drug “Reviews” for 1st Time in 2 Years
April 22, 2019
- 6 Core Elements of Recruitment Mastery
March 22, 2019
- Is Japan’s Cost-Effectiveness Assessment Scheme Cost Effective?
February 27, 2019
- Why Top-Tier Recruiters Must Embrace Their Creative Side
January 31, 2019
- Expat Truths from the Japanese Medical Device World
December 3, 2018
- Why Did the Project Take so Long?
November 16, 2018
- Finding Captains in Your Organization
October 12, 2018
- Riding the Trend: Staffing Pharma Startups in Japan
September 7, 2018
- How Having a Great CSR Program Can Help with Recruiting and Retaining Top Talent
August 16, 2018
- Rare Disease Pharmaceuticals in Japan to See New Demand for Skilled Human Resources
July 20, 2018
- 5 Billion Yen Blockbuster?
June 20, 2018
- It Is Thumbs Up for Cell Therapy in Japan
March 23, 2018
- Unique Opportunities at Pharmaceutical Companies Treating Rare Diseases
February 23, 2018
- When Leading Teams, Focus on the Principles, Not the Personalities
January 26, 2018
- What to Do about the Feeling of Torschlusspanik?
October 27, 2017
- Women! Rock the Boat and Get Promoted
September 22, 2017
- Getting the Right Message
August 25, 2017
- Putting on Your Pants
July 21, 2017
ページ
As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…
A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…
Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…